To include your compound in the COVID-19 Resource Center, submit it here.

Oct. 31 Preclinical Quick Takes: Beam licenses tech from Prime Medicine; plus BioVersys, Astellas-Kyoto University and more

Beam expands base editing platform with prime editing
Beam Therapeutics disclosed single base transitions and sickle cell disease as the first applications of its sublicense to prime editing technology from newco Prime Medicine. With the licensing deal, the two types of point

Read the full 416 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE